市場調查報告書
商品編碼
1017203

全球短效型胰島素市場:2021∼2028年

Global Short-Acting Insulin Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球短效型胰島素的市場規模在預測期間(2021年∼2028年)預計將大幅成長。

短效胰島素是一種胰島素類似物,可以非常迅速地降低高血糖水平。短效胰島素通常是人或動物的胰島素製劑,通常使用注射器皮下注射。短效胰島素有時也稱為普通胰島素或中性胰島素。

本報告提供全球短效型胰島素市場相關調查,提供市場概要,以及藥物,各流通管道,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 全球短效型胰島素市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球短效型胰島素市場-市場定義和概要

第3章 全球短效型胰島素市場-摘要整理

  • 按藥物的市場明細
  • 各流通管道的市場明細
  • 各地區的市場明細

第4章 全球短效型胰島素市場-市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球短效型胰島素市場-產業分析

  • 波特的五力分析
  • PEST分析
  • 流行病學分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球短效型胰島素市場-COVID-19分析

  • 市場上的COVID-19分析
    • COVID-19前的市場方案
    • COVID-19目前市場方案
    • COVID-19後或未來方案
  • COVID-19的價格動態
  • 需求與供給的頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 按全球短效型胰島素市場-藥物

    • 市場規模分析,及與前一年同期比較成長分析(%)、醫藥品各市場區隔
    • 醫藥品各市場區隔的市場魅力指數
  • Humalog(松鼠專業)
    • 市場規模分析,一百萬美元,2018∼2028年,及與前一年同期比較成長分析(%)、2020∼2028年
  • apidora
  • Novolog/Novorapid
  • noborin(Actrapid)
  • inshuman
  • 腐殖質
  • FIASP
  • Admelog

第8章 全球短效型胰島素市場-各流通管道

    • 市場規模分析,及與前一年同期比較成長分析(%)、各流通管道
    • 流通管道各市場區隔的市場魅力指數
  • 零售藥局
    • 市場規模分析,一百萬美元,2018∼2028年,及與前一年同期比較成長分析(%)、2020∼2028年
  • 醫院藥局
  • 線上藥局
  • 其他

第9章 全球短效型胰島素市場-各地區

    • 市場規模分析,一百萬美元,2018∼2028年,及與前一年同期比較成長分析(%)、2020∼2028年,各地區
    • 各地區的市場魅力指數
  • 北美
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%)、各產品
    • 市場規模分析,及與前一年同期比較成長分析(%)、各流通管道
    • 市場規模分析,及與前一年同期比較成長分析(%)、各國
  • 歐洲
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%)、各產品
    • 市場規模分析,及與前一年同期比較成長分析(%)、各流通管道
    • 市場規模分析,及與前一年同期比較成長分析(%)、各國
  • 南美
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%)、各產品
    • 市場規模分析,及與前一年同期比較成長分析(%)、各流通管道
    • 市場規模分析,及與前一年同期比較成長分析(%)、各國
  • 亞太地區
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%)、各產品
    • 市場規模分析,及與前一年同期比較成長分析(%)、各流通管道
    • 市場規模分析,及與前一年同期比較成長分析(%)、各國
  • 中東和非洲
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%)、各產品
    • 市場規模分析,及與前一年同期比較成長分析(%)、各流通管道

第10章 全球短效型胰島素市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準
  • 值得注意的主要企業
  • 顛覆性技術的企業
  • Start-Ups企業

第11章 全球短效型胰島素市場-企業簡介概要

  • Eli Lilly
    • 企業概要
    • 類型組合和概要
    • 主要的焦點
    • 財務概要
  • Sanofi Aventis
  • Novo Nordisk
  • Pfizer Inc
  • Biocon Ltd
  • Piramal Healthcare
  • Abbott India Ltd
  • Torrent Pharmaceuticals
  • Cadila Pharmaceuticals Ltd
  • Shreya Life Sciences Pvt.Ltd
  • Career henan chemical co
  • Biochempartner
  • BOC Sciences
  • Hubei xin bonus chemical co. LTD

清單並未網羅全面

第12章 全球短效型胰島素市場-DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式
目錄
Product Code: DMPH3494

Market Overview

The global short-acting insulin market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Short-acting insulin is a type of insulin analog that works very fast to reduce high blood sugar levels. Short-acting insulin is generally either in human or animal insulin form, usually injected subcutaneously using a syringe. Short-acting insulins may also be called regular or neutral insulin.

Market Dynamics

The short-acting insulin market growth is driven by the high usage of short-acting analogs is increasing due to the rising Type 1 diabetes population, due to sedentary lifestyles, growing geriatric population and unhealthy dietary habits, a greater number of individuals are suffering from chronic lifestyle diseases, thereby increasing the demand for short-acting insulin market.

Increasing Type 1 diabetes population globally, is expected to drive the global short-acting insulin market growth

Diabetes is a chronic, life-threatening disease with an unknown cure. It has been emerged as a global epidemic and affected millions globally. Furthermore, Type 1 diabetes is caused due to an immune system malfunction. Hence, Type 1 diabetes can be characterized most by insulin-requiring.

At present, China has the highest number of diabetes patients in the world. In addition, the prevalence of diabetes in China has risen substantially over the past decade. For instance, according to WHO, in 2020, China had about 126.80 million diabetic patients, and this number is expected to reach 138.42 million by the end of 2026. China's urbanization and growing living standards, leading to reduced physical activity and unhealthy diets, are the significant factors behind the high rate of diabetes. In 2020, China accounted for 9.8% of Type 1 diabetes patients of the total diabetes population.

Risks of short-acting insulins is likely to hinder the market growth

Short-acting insulins or neutral insulins are recombinant human insulins that were developed to mimic regular after-meal insulin release. These are intended to be used as a bolus mealtime insulin to quickly lower the increase in blood glucose (sugar) after eating. Though these are regular human insulins, they do not control the after-meal blood glucose like the insulin produced in the body. After neutral human insulin is injected, it has a delay before it is absorbed into the body. This delays the onset (usually 30 minutes) and prolongs the effect (usually 3-6 hours) of the injected regular insulin. This limit short-acting insulin's effectiveness in providing reasonable glucose control and increases the risk of hypoglycemia.

COVID-19 Impact Analysis

The COVID-19 pandemic has exerted a tremendous strain on the healthcare framework in some countries. Moreover, people with chronic conditions are more at risk if contracted by COVID-19. According to the Centers for Disease Control and Prevention, more than 30 million people in the U.S. have diabetes, a chronic disease that affects how the body turns food into energy and the body's natural insulin production. Over time, diabetes increases the risk of severe health complications, including heart disease, blindness, and nerve and kidney damage. Improvement in blood sugar control through treatment with insulin, a standard treatment, can reduce the risk of some of these long-term complications. However, diabetic patients' lives are at high risk compared to ordinary people. Therefore, the usage of short-acting insulins increased in 2021 due to COVID-19.

Segment Analysis

The Humalog segment is expected to hold largest share in this market segment

Humalog (insulin lispro) is a short-acting type of insulin. Insulin helps control blood sugar levels in diabetes mellitus, including diabetes type 1 and diabetes type 2. Humalog is more popular than other insulins. In March 2019, Eli Lilly launched the authorized generic insulin lispro injection (Humalog) in the United States. The new generic Humalog has a list price 50% lower than the Humalog list price existing in the market.

The retail Pharmacies segment is expected to hold largest share in this market segment

The retail Pharmacies segment is expected to dominate during the forecast period. Medications are easily, readily available in retail pharmacies as the generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost short-acting insulin market growth.

Geographical Analysis

North America region holds the largest market share of global short-acting insulin market

In 2020, the United States accounted for a majority of the revenue share (about 96%) in the market, mainly due to the increasing diabetic population in the country. According to a recent survey, about 9.4% of the total US population is diabetic, and about 1.75 million Americans are diagnosed with diabetes every year.

The US accounts for the highest sales of Humalog across the world, with over 56% of the market share in 2020. As a result, most diabetes drug manufacturing companies consider the country a critical market for improving overall global sales. In the United States, Humalog is available in different varieties under names, like Humalog Mix 75/25, Humalog U-100, Humalog U-200, and Humalog Mix 50/50, for the treatment of diabetes.

Competitive Landscape

The global short-acting insulin market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Sanofi Aventis, Novo Nordisk, Eli Lilly, Pfizer Inc, Biocon Ltd, Piramal Healthcare, Abbott India Ltd, Torrent Pharmaceuticals, Cadila Pharmaceuticals Ltd, Shreya Life Sciences Pvt.Ltd, Career henan chemical co, Biochempartner, BOC Sciences, Hubei xin bonus chemical co. LTD. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, On 28 May 2021 Novo Nordisk resubmited once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval.

Key Companies to Watch

Eli Lilly

Overview: Eli Lilly is an American pharmaceutical company was founded in 1876 by Colonel Eli Lilly, Headquarters located in Indianapolis, Indiana, U.S.A with more than 34,000 employees worldwide. Approximately 8,000 employees engaged in research and development and clinical research conducted in more than 55 countries with Research and development facilities located in 7 countries, Manufacturing plants located in 7 countries and Products marketed in 120 countries.

Product Portfolio: The Company's portfolio comprised of include Covid-19, Diabetes, Cancer, Immunology, Pain, Neurodegeneration.

Key Development: In June 2020, the US Food and Drug Administration (FDA) approved Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL). Eli Lilly and Company's new short-acting insulin indicated to improve glycemic control in adults with Type 1 and Type 2 diabetes. Lyumjev is a novel formulation of insulin lispro, developed to speed the absorption of insulin into the bloodstream and reduce A1C levels.

Why Purchase the Report?

  • Visualize the composition of the short-acting insulin market segmentation by drug, distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in short-acting insulin market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of short-acting insulin market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global short-acting insulin market report would provide an access to an approx. 53 market data table, 47 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Short-Acting Insulin Market - By Drug

  • Humalog (Lispro)
  • Apidra (Glulisine)
  • Novolog/Novorapid
  • Novolin (Actrapid)
  • Insuman
  • Humulin
  • FIASP
  • Admelog

Global Short-Acting Insulin Market - By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Retail Stores
  • Others

Global Short-Acting Insulin Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Short-Acting Insulin Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Short-Acting Insulin Market - Market Definition and Overview

3. Global Short-Acting Insulin Market - Executive Summary

  • 3.1. Market Snippet by Drug
  • 3.2. Market Snippet by Distribution Channel
  • 3.3. Market Snippet by Region

4. Global Short-Acting Insulin Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Type 1 diabetes population globally
    • 4.1.2. Restraints:
      • 4.1.2.1. Some risks of short-acting insulins
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Short-Acting Insulin Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Epidemiology Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. Global Short-Acting Insulin Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Short-Acting Insulin Market - By Drug

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Segment
    • 7.1.2. Market Attractiveness Index, By Drug Segment
  • 7.2. Humalog (Lispro)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Apidra (Glulisine)
  • 7.4. Novolog/Novorapid
  • 7.5. Novolin (Actrapid)
  • 7.6. Insuman
  • 7.7. Humulin
  • 7.8. FIASP
  • 7.9. Admelog

8. Global Short-Acting Insulin Market - By Distribution channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel Segment
    • 8.1.2. Market Attractiveness Index, By Distribution channel Segment
  • 8.2. Retail Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Hospital Pharmacies
  • 8.4. Online Pharmacies
  • 8.5. Others

9. Global Short-Acting Insulin Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Global Short-Acting Insulin Market - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking
  • 10.4. Key Companies to Watch
  • 10.5. Company with disruptive technology
  • 10.6. Start Up Companies

11. Global Short-Acting Insulin Market- Company Profiles

  • 11.1. Eli Lilly*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Sanofi Aventis
  • 11.3. Novo Nordisk
  • 11.4. Pfizer Inc
  • 11.5. Biocon Ltd
  • 11.6. Piramal Healthcare
  • 11.7. Abbott India Ltd
  • 11.8. Torrent Pharmaceuticals
  • 11.9. Cadila Pharmaceuticals Ltd
  • 11.10. Shreya Life Sciences Pvt.Ltd
  • 11.11. Career henan chemical co
  • 11.12. Biochempartner
  • 11.13. BOC Sciences
  • 11.14. Hubei xin bonus chemical co. LTD

LIST NOT EXHAUSTIVE

12. Global Short-Acting Insulin Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us